StreetInsider.com News Articles

Form DEFA14A Cardiff Oncology, Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981546.html

Form DEFA14A Cardiff Oncology, Inc.

Wed, 26 Aug 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260826/26981546.html

Form DEF 14A Cardiff Oncology, Inc. For: Aug 26

Wed, 26 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26981404.html

Form DEF 14A Cardiff Oncology, Inc. For: Aug 26

Wed, 26 Aug 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260826/26981404.html

Form PRE 14A Cardiff Oncology, Inc. For: Aug 14

Fri, 14 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26929920.html

Form PRE 14A Cardiff Oncology, Inc. For: Aug 14

Fri, 14 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26929920.html

William Blair Downgrades Cardiff Oncology (CRDF) to Market Perform

Wed, 12 Aug 2026 02:28:39 -0400

William Blair analyst Andy T. Hsieh downgraded Cardiff Oncology (NASDAQ: CRDF) from Outperform to Market Perform.

The analyst comments: “After markets closed on Tuesday, August 11, Cardiff reported second-quarter financial results and provided an update on recent progress.

We are downgrading Cardiff shares to Market Perform as company fundamentals have deteriorated materially. Specifically, we believe the uncertainty associated with onvansertib rights, coupled with the need to raise additional capital prior to initiating the Phase III study, creates an adverse risk/reward profile. As such, we are downgrading Cardiff to Market Perform.”

For an analyst ratings summary and ratings history on Cardiff Oncology click

William Blair Downgrades Cardiff Oncology (CRDF) to Market Perform

Wed, 12 Aug 2026 02:28:39 -0400

William Blair analyst Andy T. Hsieh downgraded Cardiff Oncology (NASDAQ: CRDF) from Outperform to Market Perform.

The analyst comments: “After markets closed on Tuesday, August 11, Cardiff reported second-quarter financial results and provided an update on recent progress.

For an analyst ratings summary and ratings history on Cardiff Oncology click

Cardiff Oncology, Inc. (CRDF) Misses Q2 EPS by 2c

Tue, 11 Aug 2026 16:38:50 -0400

Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q2 EPS of ($0.14), $0.02 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $62.78 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.

Form 8-K Cardiff Oncology, Inc. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905815.html

Form 8-K Cardiff Oncology, Inc. For: Aug 11

Tue, 11 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260811/26905815.html

Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update

Tue, 11 Aug 2026 16:10:00 -0400

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC